Minireviews Open Access
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Nov 6, 2014; 3(4): 237-242
Published online Nov 6, 2014. doi: 10.5527/wjn.v3.i4.237
Role of insulin resistance in uric acid nephrolithiasis
Hanhan Li, Dane E Klett, Raymond Littleton, Jack S Elder, Jesse D Sammon, VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Health System, Detroit, MI 48202, United States
Author contributions: Li H and Klett DE drafted and finalized the manuscript; Elder JS, Littleton R and Sammon JD critically revised the manuscript.
Correspondence to: Jesse D Sammon, DO, VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Health System, 2799 W. Grand Boulevard, Detroit, MI 48202, United States. jsammon79@gmail.com
Telephone: +1-207-6927167 Fax: +1-313-9164352
Received: June 25, 2014
Revised: July 21, 2014
Accepted: September 4, 2014
Published online: November 6, 2014
Processing time: 135 Days and 6.5 Hours

Abstract

Metabolic syndrome has been implicated in the pathogenesis of uric acid stones. Although not completely understood, its role is supported by many studies demonstrating increased prevalence of uric acid stones in patients with metabolic syndrome and in particular insulin resistance, a major component of metabolic syndrome. This review presents epidemiologic studies demonstrating the association between metabolic syndrome and nephrolithiasis in general as well as the relationship between insulin resistance and uric acid stone formation, in particular. We also review studies that explore the pathophysiologic relationship between insulin resistance and uric acid nephrolithiasis.

Key Words: Nephrolithiasis; Kidney calculi; Uric acid; Insulin resistance; Metabolic syndrome

Core tip: Increasing awareness of the association between prevalence of metabolic syndrome and uric acid nephrolithiasis has caused a closer examination into modifiable risk factors for stone recurrence. The mechanism behind this association is thought to be due to decreased ammoniagenesis as caused by insulin resistance in the proximal tubule of the kidney. The presence or recurrence of uric acid stones should prompt the physician to look for traits of metabolic syndrome. Further studies into this causal relationship may provide additional medical interventions to decrease incident stones.



INTRODUCTION

In the United States, the prevalence of kidney stones has risen since 1976 and was estimated to be 8.8% in 2010[1,2]. The magnitude of this problem is exacerbated by a recurrence rate as high as 50% within 5 years[3]. The prevalence of kidney stones is largely dependent on many un-modifiable patient factors including gender, ethnicity, and geography[1]. However, a growing interest in the relationship between modifiable risk factors such as obesity, diabetes mellitus (DM) and metabolic syndrome (MetS) has developed in light of the increasing prevalence of these conditions[4].

The majority of kidney stones are calcium-based with uric acid (UA) nephrolithiasis comprising only 10% of calculi in the overall stone-forming population[5]. However, UA stones disproportionally affect certain cohorts. Among obese patients, UA nephrolithiasis accounts for up to 63% of the stone burden[6].

The central role insulin resistance appears to play in UA stone formation has been the subject of much research and debate. The exploration of this important relationship is the purpose of the current review. We first present epidemiologic studies that demonstrate the link between MetS and nephrolithiasis in general. We then highlight studies examining the increased prevalence of UA stones in patients with insulin resistance. Finally, we review currently accepted pathophysiologic mechanisms that support the role of insulin resistance in UA stone formation.

METABOLIC SYNDROME AND NEPHROLITHIASIS

MetS comprises traits of insulin resistance (IR), obesity, hypertension (HTN), and hyperlipidemia. Multiple studies demonstrate that MetS and its constituent components are associated with increased risk of kidney stones (Table 1).

Table 1 Insulin resistance and kidney stone formation.
Ref.TypeYearnStudy populationRelevant variablesConclusion
Taylor et al[8]Prospective2005241623Health professionals from 3 different study cohorts starting as early as 1980Patient reported BMI, waist circumference, and incidence of nephrolithiasisObesity, weight gain, and waist circumference are positively associated with renal stone disease
Taylor et al[7]Cross-sectional2005220478Health professionalsPatient reported incidence of diabetes and kidney stonesPatients with DM have higher relative risk of having stones. Patients with kidney stones were more likely to develop DM
Rendina et al[27]Cross-Sectional, single institution20092132Consecutive Caucasian inpatients in a single Italian hospitalAHA/NHLBI criteria for MetS diagnosis, kidney stones diagnosed on USMetS, specifically HTN and obesity (in females) is significantly associated with US evidence of kidney stones
Chang et al[28]Prospective, single institution20113872South Korean workers participating in comprehensive health exam from 2002-2009National Cholesterol Education Program’s Third Adult Treatment Panel criteria for MetS diagnosis, kidney stone diagnosed on USMetS is significantly associated with acidified urine and increased risk of kidney stones MetS over time as well as each additional MetS trait predicted development of kidney stones
Kabeya et al[9]Cross-Sectional, single institution20122717Japanese patients undergoing MetS screeningFasting serum insulin, FPG, HbA1c, US for diagnosis of kidney stoneGlycemic control may be an independent risk factor for kidney stones. The number of MetS traits is positively associated with kidney stone risk; specifically, patients with all 5 traits are at a 2.7 x increased risk of kidney stones compared to those with 2 traits
Kohjimoto et al[29]Cross-Sectional201311555Japanese surveyMetS traits, incident kidney stones – multiple and recurrentIncreasing number of MetS traits increased stone burden

One of the largest studies to examine the link between components of MetS and nephrolithiasis was by Taylor et al[7] who reported a cross-sectional analysis of three large national patient surveys: Nurses Health Study I, Nurses Health Study II, and Health Professionals Follow-Up Study. This investigation included over 200000 health professional males and female nurses responding to surveys administered every 2 years with an age range of 25 to 75 years of age. The study concluded that DM type II was significantly associated with kidney stone formation with a relative risk of 1.38 in older women, 1.67 in younger women, and 1.31 in men as compared to non-diabetic patients after controlling for age, body-mass index (BMI), thiazide use, and diet. Additionally, they reported that among patients with kidney stones, the relative risk of developing diabetes was 1.33 in older women, 1.48 in younger women, and 1.49 in men as compared to patients without nephrolithiasis. In a separate analysis of these data, Taylor et al[8] reported that obesity, weight gain, and waist circumference were risk factors for incident kidney stones. Together, these studies support the underlying connection between the main components of MetS and kidney stones. While the conclusions of these studies are strengthened by the very large size of the study cohort, the analysis is likely biased by the use of self-reported outcomes in these datasets.

In another large study, Kabeya et al[9] showed a significant association between certain traits of MetS and kidney stone formation in 2717 healthy Japanese individuals. Traits significantly associated with increased risk of kidney stone formation included glucose intolerance (fasting plasma glucose ≥ 100 mg/dL, OR 1.53) and HTN (Systolic ≥ 130 mmHg, Diastolic ≥ 85 mmHg, OR 1.42). In addition, they demonstrated a dose-dependent relationship between metabolic syndrome traits and kidney stone formation. The odds of patients with three or more traits of MetS (abdominal obesity, glucose intolerance, HTN, hypertriglyceridemia, and/or low high density lipoprotein) developing kidney stones was 1.48 times higher than those without these traits. This association was not shown for patients with two or fewer traits of MetS. This finding is especially important, as a dose dependent response suggests a causal link between MetS and kidney stones. Although this study provides robust evidence for this association, it was limited by inclusion of a single Japanese population, reducing generalizability to other at risk populations. In addition, the cross-sectional study design confounds the temporal relationship between kidney stone formation and MetS.

INSULIN RESISTANCE INCREASES RISK OF URIC ACID NEPHROLITHIASIS

Because different types of kidney stones have a tendency to form in different urine milieus, there has been substantial interest in studying the link between insulin resistance and UA stone formation. Low urine pH is a factor of both insulin resistance and UA stone formation; it has therefore been hypothesized that MetS should favor the formation of UA stones[10]. Multiple studies performed stone analyses in order to query the relationship between insulin resistance and specific kidney stone type (Table 2). In a study of 2464 kidney stone formers, Daudon et al[10] found that in patients with DM, UA stones accounted for 35.7% of all stones while only 11% in non-diabetic patients, P < 0.0001. The authors recommended that patients with UA stones should be evaluated for insulin resistance or MetS as the prevalence of DM in the UA stone population (27.8%) was significantly higher than the prevalence of DM in the population forming other stone types (6.9%).

Table 2 Insulin resistance and uric acid stone formation.
Ref.TypeYearnStudy populationRelevant variablesConclusion
Lieske et al[30]Retrospective, Case Control, single county in Minnesota20067122Known stone former vs ControlStone analysis, metabolic evaluationDM, obesity, and HTN are associated with the development of kidney stones. DM is significantly associated with UA stone formation
Daudon et al[10]Cross-sectional20062464DM vs Non-DM stone formersStone analysis, BMI, clinical and lab data in a subset of stone formersDM is associated with a higher overall frequency of kidney stones, specifically, UA. UA stone formation can reflect IR and patients should be evaluated for MetS and/or DM if UA stones are diagnosed.
Akman et al[11]Retrospective, single institution2012146MetS vs Non-MetS undergoing PCNLKidney stone analysis, imaging for initial/recurrent kidney stone diagnosis, baseline blood chemistry and urinalysisPatients with MetS have a higher frequency of UA stones (21.9% vs 4.1%) and a higher rate of all stone recurrence following PCNL
Cho et al[12]Retrospective, three institutions2012712MetS vs Non-MetS undergoing endourologic intervention for stonesStone analysis, metabolic data, International Diabetes Federation definition for MetSMetS, specifically the traits of impaired fasting glucose and hypertriglyceridemia, is significantly associated with UA stone formation, but calcium based stones remain most common in this group
Kadlec et al[31]Retrospective, single institution2012590All stone formers undergoing endourologic interventionStone analysis, MetS factors (presence of obesity, DM, HTN, and HL)DM and HTN, components of MetS, are significantly associated with UA containing stones
Stansbridge et al[32]Retrospective, single institution20131504UA stone formers vs Non-UA24H urine, stone analysis, relevant underlying diagnoses, including DMUA containing stones are increased in DM, but calcium containing stones are still the most common in DM
Inci et al[33]Case-control, single institution201299Control vs Stone formers (sub-stratified by stone type)Stone analysis, metabolic evaluationBMI and Hyperlipidemia, two major traits of IR/MetS, are significantly associated with calcium and UA stone formation
Zhou et al[34]Retrospective, single institution2013269UA stone formers vs Non-UA stone formers undergoing PCNLCT for visceral fat area measurement, stone analysis, metabolic evaluationHTN and visceral fat area, two traits highly associated with IR/MetS, are independent risk factors associated with UA stone formation

Other studies have also demonstrated increased odds of UA stones in patients with MetS. In particular, Akman et al[11] found UA stones to be significantly more common in patients with MetS compared to patients without MetS (21.9% vs 4.1%, P < 0.001) in a group of 146 stone formers. Furthermore, the authors suggested that patients with MetS may be more susceptible to UA stone recurrence. In their study, a trend toward higher recurrence of UA stone formation was demonstrated in patients with MetS as compared to patients without MetS (42.9% vs 0%, P = 0.51). Although a statistically significant association was not found, the study may have been underpowered to detect a difference. Therefore, a relationship between MetS and UA stone recurrence may exist, and further study is required.

In a separate study of UA stone formation in MetS, Cho et al[12] showed that MetS was an independent risk factor for UA stone. In an analysis of individual MetS traits, a direct relationship between UA stone and MetS traits was uncovered: as the number of MetS traits increased, the risk for UA stones increased (10.2% in patients with one MetS trait and as high as 30.4% with four components). These studies are limited by their use of cross-sectional or retrospective designs. Nevertheless, the relationship between UA stones and MetS established by these studies should prompt physicians to evaluate patients presenting with UA stones for underlying insulin resistance and related comorbidities.

PATHOPHYSIOLOGY OF URIC ACID STONE FORMATION IN PATIENTS WITH INSULIN RESISTANCE

The pathophysiologic basis for UA stone formation in patients with insulin resistance has been widely studied and a summary of important articles on this subject can be found in Table 3. Surprisingly, UA stone formation in insulin resistance does not depend on the presence of more UA in the urine. In fact, several studies revealed that insulin resistance decreases UA clearance[13,14]. This finding suggests that another causal mechanism may be responsible for UA nephrolithiasis in patients with insulin resistance. Clinically, UA stone formers have low urinary pH. Pak et al[15] studied 56 pure and mixed UA stone formers and 68 control subjects. Patients were instructed to consume a calorie restricted diet and maintain high fluid intake. They showed that UA stone formers had higher serum UA levels but lower urinary UA levels. Urinary pH was 5.34 in UA stone formers compared to 6.17 in control subjects. This study suggests that it may be low urine pH rather than elevated urine UA levels that plays a critical role in UA stone formation.

Table 3 Pathophysiologic relationship between insulin resistance and uric acid stone formation.
Ref.Study TypeYearnStudy populationOutcomesConclusion
Facchini et al[13]Cross-sectional, single institution199136Healthy volunteers with varying degrees of IR24H urine (pH, UA), UA clearance, steady-state plasma glucose, metabolic evaluationAs IR increases serum UA increases and urinary UA clearance decreases. Thus, increased serum UA concentration may be considered an additional trait of MetS
Cappuccio et al[14]Cross-sectional, single institution1993568Factory volunteersFasting spot urine (UA), fractional excretion of Na+, fasting blood analysisThe higher the serum UA level, the greater the amount of renal Na+ reabsorption. This phenomenon is consistent with hyperinsulinemia, and possibly IR, as insulin is known to increase renal sodium reabsorption
Pak et al[15]Retrospective, single institution200156UA stone formers vs matched control with diet control24H urineUA stone formers have increased serum UA, decreased fractional excretion of urinary UA, and decreased urinary pH
Sakhaee et al[16]Prospective, single institution200270Healthy vs stone formers (UA vs Calcium vs Mixed) with diet control24H urine (pH, NH4+), fasting glucoseUA stone formers are more likely to have IR/DM. UA stone formation occurs due to impaired NH4+ excretion and urine acidification. Acid loading further decreases urinary pH in these patients as compared to non-UA stone formers/Controls
Abate et al[17]Prospective, single institution200468Stone free patients vs UA stone formers with diet control24H urine (pH, NH4+), glucose disposal rateAcute hyperinsulinemia leads to elevated urinary pH and NH4+ excretion in normal insulin-sensitive subjects. Alternatively, IR is associated with low urinary pH and impaired NH4+ excretion and could be renal manifestations of IR causing UA stone formation
Maalouf et al[23]Cross-sectional, single institution2007148MetS vs No MetS (all stone free)24H urine (pH, NH4+), Homeostasis model for IR, metabolic evaluationAcidic urine is a feature of MetS and is associated with the degree of IR. As MetS traits increase, urine pH decreases
Bobulescu et al[24]Prospective, single institution201335Matched patients with and without UA stones, matched non-stone forming diabetic controls24H urine, urinary ammonium excretionBoth uric acid non-diabetic patients as well as DM non-stone forming patients had lower urinary pH as compared to matched non-stone forming non-diabetic controls
Cameron et al[25]Prospective, single institution201119UA stone formers vs normal controls with diet control24H urine, diurnal urinary pHUA stone formers had decreased urinary pH with increased undissociated UA secretion compared to normal controls

In 2002, Sakhaee et al[16] published a key study revealing a defect in urinary ammoniagenesis among UA stone formers. After equilibrating to a control diet, UA stone formers demonstrated lower urinary pH and decreased urinary ammonium excretion as compared to normal controls and calcium stone formers. Furthermore, after patients were given an acidic load, pure and mixed UA stone formers experienced a greater degree of urine acidification when compared to both normal controls and calcium stone formers. These findings suggest that although diet has a strong impact on stone formation, patients forming UA stones may be at a particular disadvantage relative to their calcium stone forming peers at any level of diet acidity.

Given the above findings, it is reasonable to ask what is unique about UA stone formers that could cause this defect in urinary acid handling. Abate et al[17] revealed that insulin resistance is a driver of low urinary ammonium and pH. UA stone formers and healthy volunteers underwent a study in which they were maintained at a steady state diet and were given controlled doses of insulin (hyperinsulinemic-euglycemic procedure). Baseline 24-h urine collection revealed evidence of lower urinary pH, lower citrate excretion, higher net acid excretion and lower ammonium excretion in the UA stone formers. This suggests that the acid that is secreted is not being buffered adequately by ammonium. They also noted (though not statistically significant) that UA stone formers with progressively lower urine pH tended to have lower glucose disposal rates (insulin resistance).

The specific mechanism for urinary acidification has been suggested by several novel in vitro studies. Insulin receptors are expressed in the renal tubular epithelium, and insulin stimulates the renal tubular sodium-hydrogen exchanger (Na+/H+ exchanger) to increase reabsorption of hydrogen[18,19]. The activation and up-regulation of the Na+/H+ exchanger by insulin promotes ionic trapping of ammonia in the renal tubule; hydrogen ions become bound to ammonia, which is converted to ammonium and is unable to exit the lumen of the renal tubule[20-22]. Resistance to insulin thereby results in decreased buffering capacity for urinary acidification due to decreased ammonia secretion.

The critical relationship between MetS and urine acidification has been supported by Maalouf et al[23] who showed that non-stone formers with MetS had decreasing urinary pH with increasing number of MetS traits. Their work supports the theory that insulin resistance plays a role in renal acid handling causing decreased ammoniagenesis and thereby increasing risk of UA stone formation.

Though insulin resistance appears to be playing a significant role in UA stone formation, not all DM patients go on to develop UA stones. This principle was explored by Bobulescu et al[24], who prospectively studied BMI-matched non-diabetic pure UA stones formers, diabetic non-stone formers and non-stone forming non-diabetic control patients. Their results demonstrated that both non-diabetic UA stone formers as well as diabetic non-stone forming patients have decreased urinary pH as compared to matched non-diabetic non-stone forming controls. However, non-diabetic patients with UA stones have impaired ability to secrete ammonium after acid loading as compared to diabetic and non-diabetic control patients without nephrolithiasis[24]. This suggests that while insulin resistance plays a role in UA stone formation, additional derangements may occur in these UA stone formers as compared to non-stone formers with DM.

Another salient and surprising feature of studies examining 24-h urine chemistries in UA stone formers vs non-stone formers is a frequent absence of difference in urine chemistries. Cameron et al[25] discovered a significant diurnal variation in urine acidification occurring in UA stone formers. This intermittent elevation in urinary acid levels leads to transiently lower urine pH, allowing for the precipitation of UA, despite a relatively normal 24-h urine chemistry.

MANAGEMENT RECOMMENDATIONS

Currently, the American Urologic Association guidelines recommend metabolic testing for recurrent stone formers and high-risk stone patients[26]. This work-up includes an initial 24-h urine chemistry followed by repeat testing if stones recur or after initiation of therapy. For patients with UA stones, fluid intake should be sufficient for 2.5 liters of urine output and dietary changes aimed at limiting animal protein, a key driver of urinary acid levels. Additionally, potassium citrate should be recommended to alkalinize the urine (increase urine pH) in an effort to decrease recurrence of UA stones. Nevertheless, these management guidelines do not address the underlying mechanism responsible for UA stone formation in insulin resistance. Further research targeting the defects in ammoniagenesis in insulin resistance may yield novel therapies for this challenging clinical problem.

CONCLUSION

This review explores the relationship between UA nephrolithiasis and insulin resistance. Several epidemiologic studies identify the association between insulin resistance and kidney stones, specifically UA stones. The mechanism underlying this association relates to the importance of renal insulin receptors in acid handling. Insulin resistance results in impaired excretion of urinary ammonia leading to lower urinary pH. Ultimately, these conditions induce UA precipitation out of the urine, leading to the formation of UA stones. As one of the key components of metabolic syndrome, insulin resistance should be suspected in patients with recurrent UA nephrolithiasis, and attention should be directed to the other components of metabolic syndrome, including hypertension, dyslipidemia, and obesity.

Footnotes

P- Reviewer: Bellomo G, Wagner CA S- Editor: Ji FF L- Editor: A E- Editor: Lu YJ

References
1.  Scales CD, Smith AC, Hanley JM, Saigal CS. Prevalence of kidney stones in the United States. Eur Urol. 2012;62:160-165.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1738]  [Cited by in F6Publishing: 1590]  [Article Influence: 132.5]  [Reference Citation Analysis (0)]
2.  Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int. 2003;63:1817-1823.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 949]  [Cited by in F6Publishing: 929]  [Article Influence: 44.2]  [Reference Citation Analysis (0)]
3.  Ljunghall S. Incidence of upper urinary tract stones. Miner Electrolyte Metab. 1987;13:220-227.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care. 2004;27:2444-2449.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1028]  [Cited by in F6Publishing: 985]  [Article Influence: 49.3]  [Reference Citation Analysis (0)]
5.  Mandel NS, Mandel GS. Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. J Urol. 1989;142:1516-1521.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Ekeruo WO, Tan YH, Young MD, Dahm P, Maloney ME, Mathias BJ, Albala DM, Preminger GM. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol. 2004;172:159-163.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 154]  [Cited by in F6Publishing: 155]  [Article Influence: 7.8]  [Reference Citation Analysis (0)]
7.  Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int. 2005;68:1230-1235.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 318]  [Cited by in F6Publishing: 348]  [Article Influence: 19.3]  [Reference Citation Analysis (0)]
8.  Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293:455-462.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 760]  [Cited by in F6Publishing: 738]  [Article Influence: 38.8]  [Reference Citation Analysis (0)]
9.  Kabeya Y, Kato K, Tomita M, Katsuki T, Oikawa Y, Shimada A, Atsumi Y. Associations of insulin resistance and glycemic control with the risk of kidney stones. Intern Med. 2012;51:699-705.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 24]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
10.  Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol. 2006;17:2026-2033.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 192]  [Cited by in F6Publishing: 204]  [Article Influence: 11.3]  [Reference Citation Analysis (0)]
11.  Akman T, Binbay M, Erbin A, Tepeler A, Sari E, Kucuktopcu O, Ozgor F, Muslumanoglu A. The impact of metabolic syndrome on long-term outcomes of percutaneous nephrolithotomy (PCNL). BJU Int. 2012;110:E1079-E1083.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 16]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
12.  Cho ST, Jung SI, Myung SC, Kim TH. Correlation of metabolic syndrome with urinary stone composition. Int J Urol. 2013;20:208-213.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 45]  [Cited by in F6Publishing: 54]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
13.  Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008-3011.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 445]  [Cited by in F6Publishing: 440]  [Article Influence: 13.3]  [Reference Citation Analysis (0)]
14.  Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA. 1993;270:354-359.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 136]  [Cited by in F6Publishing: 129]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
15.  Pak CY, Sakhaee K, Peterson RD, Poindexter JR, Frawley WH. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 2001;60:757-761.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 124]  [Cited by in F6Publishing: 133]  [Article Influence: 5.8]  [Reference Citation Analysis (0)]
16.  Sakhaee K, Adams-Huet B, Moe OW, Pak CY. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int. 2002;62:971-979.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 212]  [Cited by in F6Publishing: 228]  [Article Influence: 10.4]  [Reference Citation Analysis (0)]
17.  Abate N, Chandalia M, Cabo-Chan AV, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65:386-392.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 361]  [Cited by in F6Publishing: 367]  [Article Influence: 18.4]  [Reference Citation Analysis (0)]
18.  Fuster DG, Bobulescu IA, Zhang J, Wade J, Moe OW. Characterization of the regulation of renal Na+/H+ exchanger NHE3 by insulin. Am J Physiol Renal Physiol. 2007;292:F577-F585.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 80]  [Cited by in F6Publishing: 81]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
19.  Chobanian MC, Hammerman MR. Insulin stimulates ammoniagenesis in canine renal proximal tubular segments. Am J Physiol. 1987;253:F1171-F1177.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Nagami GT. Luminal secretion of ammonia in the mouse proximal tubule perfused in vitro. J Clin Invest. 1988;81:159-164.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 81]  [Cited by in F6Publishing: 87]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
21.  Bobulescu IA, Moe OW. Luminal Na(+)/H (+) exchange in the proximal tubule. Pflugers Arch. 2009;458:5-21.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 94]  [Cited by in F6Publishing: 86]  [Article Influence: 5.7]  [Reference Citation Analysis (0)]
22.  Klisic J, Hu MC, Nief V, Reyes L, Fuster D, Moe OW, Ambühl PM. Insulin activates Na(+)/H(+) exchanger 3: biphasic response and glucocorticoid dependence. Am J Physiol Renal Physiol. 2002;283:F532-F539.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007;2:883-888.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 190]  [Cited by in F6Publishing: 200]  [Article Influence: 11.8]  [Reference Citation Analysis (0)]
24.  Bobulescu IA, Maalouf NM, Capolongo G, Adams-Huet B, Rosenthal TR, Moe OW, Sakhaee K. Renal ammonium excretion after an acute acid load: blunted response in uric acid stone formers but not in patients with type 2 diabetes. Am J Physiol Renal Physiol. 2013;305:F1498-F1503.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 28]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
25.  Cameron M, Maalouf NM, Poindexter J, Adams-Huet B, Sakhaee K, Moe OW. The diurnal variation in urine acidification differs between normal individuals and uric acid stone formers. Kidney Int. 2012;81:1123-1130.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 39]  [Article Influence: 3.3]  [Reference Citation Analysis (0)]
26.  Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM. Medical Management of Kidney Stones: AUA Guideline. J Urol. 2014;192:316-324.  [PubMed]  [DOI]  [Cited in This Article: ]
27.  Rendina D, Mossetti G, De Filippo G, Benvenuto D, Vivona CL, Imbroinise A, Zampa G, Ricchio S, Strazzullo P. Association between metabolic syndrome and nephrolithiasis in an inpatient population in southern Italy: role of gender, hypertension and abdominal obesity. Nephrol Dial Transplant. 2009;24:900-906.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 77]  [Cited by in F6Publishing: 77]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
28.  Chang IH, Lee YT, Lee DM, Kim TH, Myung SC, Kim YS, Ahn SH. Metabolic syndrome, urine pH, and time-dependent risk of nephrolithiasis in Korean men without hypertension and diabetes. Urology. 2011;78:753-758.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 18]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
29.  Kohjimoto Y, Sasaki Y, Iguchi M, Matsumura N, Inagaki T, Hara I. Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis. 2013;61:923-929.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 107]  [Cited by in F6Publishing: 120]  [Article Influence: 10.9]  [Reference Citation Analysis (0)]
30.  Lieske JC, de la Vega LS, Gettman MT, Slezak JM, Bergstralh EJ, Melton LJ, Leibson CL. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis. 2006;48:897-904.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 97]  [Cited by in F6Publishing: 104]  [Article Influence: 6.1]  [Reference Citation Analysis (0)]
31.  Kadlec AO, Greco K, Fridirici ZC, Hart ST, Vellos T, Turk TM. Metabolic syndrome and urinary stone composition: what factors matter most? Urology. 2012;80:805-810.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 50]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
32.  Stansbridge EM, Griffin DG, Walker V. Who makes uric acid stones and why--observations from a renal stones clinic. J Clin Pathol. 2013;66:426-431.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 7]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
33.  Inci M, Demirtas A, Sarli B, Akinsal E, Baydilli N. Association between body mass index, lipid profiles, and types of urinary stones. Ren Fail. 2012;34:1140-1143.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 38]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
34.  Zhou T, Watts K, Agalliu I, DiVito J, Hoenig DM. Effects of visceral fat area and other metabolic parameters on stone composition in patients undergoing percutaneous nephrolithotomy. J Urol. 2013;190:1416-1420.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 15]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]